Top Cannabis Investment News, Member Posts, Cannabis Investment Daily Indices and more!

1yr ago Cannabis greenmarketreport Views: 384

-

Georgians may have to wait a little bit longer to buy low-THC medical marijuana from dispensaries this year.

The Georgia Access to Medical Cannabis Commission gathered for a special session on Thursday to roll back a unanimous approval they made last week regarding new major rules for their medical program, Fox 5 Atlanta reported.

The commission forgot to notify the Office of Legislative Counsel about Jan. 25 meeting to pass testing, inspections, and distribution rules – a requirement explicitly outlined in the state law.

Chairman Sid Johnson said during the Thursday session that the body is “committed to conducting its business correctly and transparently, therefore we are here today to rescind the motions adopted” during the meeting.

Johnson said that the office had realized a notice of the meeting was not sent to the Office of Legislative Counsel when filings to certify the approved rules began.

The committee said it would post a meeting notice on Monday with a new date to pass the rules again. The state has been aiming to open stores for business by spring.

Georgia’s vertical medical market has been slowly crawling toward a launch for two years now, six years after a law permitted patients to consume yet didn’t allow them to buy it in the state.

The limited program is capped at six companies and only allows nonsmokable forms of low-THC marijuana (5% or less by volume). Two companies will be able to produce in 100,000 square-foot facilities – Botanical Sciences and Trulieve – while the other four are restricted to facilities half the size. All six will be allowed to open up to five dispensaries.

The rollout has had its fair share of criticism and lawsuits. Just last month, five companies who lost their bids for licenses joined forces to file suit against the state, saying that the process was corrupt.

Efforts to challenge the state’s licensing decisions has evolved since 15 of the 69 companies that applied for the six licenses filed protests over a lack of transparency in the scoring process, the Atlanta-Journal Constitution reported at the time.

Georgia Medical Cannabis Program Rules Delayed over Technicality on Green Market Report.


Today's Cannabis Investment Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.